An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models

Citations Over TimeTop 10% of 2016 papers

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease associated with aggregation of TAR DNA-binding protein-43 (TDP-43) in neuronal cells and manifests as motor neuron dysfunction &muscle atrophy. The carboxyl-terminal prion-like domain of TDP-43 can aggregate in vitro into toxic β-sheet rich amyloid-like structures. So far, treatment options for ALS are very limited and Riluzole, which targets glutamate receptors, is the only but highly ineffective drug. Therefore, great interest exists in developing molecules for ALS treatment. Here, we have examined certain derivatives of acridine containing same side chains at position 4 &5, for inhibitory potential against TDP-43 aggregation. Among several acridine derivatives examined, AIM4, which contains polar carboxyl groups in the side arms, significantly reduces TDP-43-YFP aggregation in the powerful yeast model cell and also abolishes in vitro amyloid-like aggregation of carboxyl terminal domain of TDP-43, as observed by AFM imaging. Thus, AIM4 can be a lead molecule potentiating further therapeutic research for ALS.

Related Papers

• → Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis(2020)143 cited
• → Riluzole for the Treatment of Amyotrophic Lateral Sclerosis(2020)77 cited
• → Riluzole(1996)206 cited
• → Effects of riluzole on symptom progression in amyotrophic lateral sclerosis(1997)22 cited
• Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole.(2007)